
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8143028/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanoparticle protein corona evolution: from biological impact to biomarker discovery. Nanoscale, 2022, 14, 1606-1620.	2.8	25
2	Engineered nanoparticles enable deep proteomics studies at scale by leveraging tunable nano–bio interactions. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2106053119.	3.3	29
3	Analysis of the Human Plasma Proteome Using Multiâ€Nanoparticle Protein Corona for Detection of Alzheimer's Disease. Advanced Healthcare Materials, 2021, 10, e2000948.	3.9	19
4	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 2021, 266, 120431.	5.7	131
5	Nano–Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection. Accounts of Chemical Research, 2021, 54, 291-301.	7.6	95
6	Staneneâ€Based Nanosheets for βâ€Elemene Delivery and Ultrasoundâ€Mediated Combination Cancer Therapy. Angewandte Chemie, 2021, 133, 7231-7240.	1.6	12
7	Staneneâ€Based Nanosheets for βâ€Elemene Delivery and Ultrasoundâ€Mediated Combination Cancer Therapy. Angewandte Chemie - International Edition, 2021, 60, 7155-7164.	7.2	113
8	Targeted delivery of protein arginine deiminase-4 inhibitors to limit arterial intimal NETosis and preserve endothelial integrity. Cardiovascular Research, 2021, 117, 2652-2663.	1.8	24
9	Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Science Translational Medicine, 2021, 13, .	5.8	111
10	Biomaterials and nanomedicine for bone regeneration: Progress and future prospects. Exploration, 2021, 1, 20210011.	5.4	90
11	Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials, 2020, 234, 119760.	5.7	89
12	A materials-science perspective on tackling COVID-19. Nature Reviews Materials, 2020, 5, 847-860.	23.3	228
13	Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nature Communications, 2020, 11, 3662.	5.8	175
14	Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers. Angewandte Chemie - International Edition, 2020, 59, 19787-19795.	7.2	88
15	siRNA nanoparticles targeting CaMKIIÎ <sup>3</sup> in lesional macrophages improve atherosclerotic plaque stability in mice. Science Translational Medicine, 2020, 12, .	5.8	132
16	Plattformen für die orale Insulinabgabe: Strategien zur Beseitigung der biologischen Barrieren. Angewandte Chemie, 2020, 132, 19955-19964.	1.6	5
17	Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy. Nano Letters, 2020, 20, 4857-4863.	4.5	42
18	Germanene-Based Theranostic Materials for Surgical Adjuvant Treatment: Inhibiting Tumor Recurrence and Wound Infection. Matter, 2020, 3, 127-144.	5.0	190

#	Article	IF	CITATIONS
19	Marriage of black phosphorus and Cu2+ as effective photothermal agents for PET-guided combination cancer therapy. Nature Communications, 2020, 11, 2778.	5.8	233
20	Nanostructure Engineering by Simple Tuning of Lipid Combinations. Angewandte Chemie, 2020, 132, 6308-6311.	1.6	2
21	ROS-Mediated Selective Killing Effect of Black Phosphorus: Mechanistic Understanding and Its Guidance for Safe Biomedical Applications. Nano Letters, 2020, 20, 3943-3955.	4.5	158
22	Phosphorus Science-Oriented Design and Synthesis of Multifunctional Nanomaterials for Biomedical Applications. Matter, 2020, 2, 297-322.	5.0	165
23	Nanostructure Engineering by Simple Tuning of Lipid Combinations. Angewandte Chemie - International Edition, 2020, 59, 6249-6252.	7.2	19
24	Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy. Nano Letters, 2020, 20, 1637-1646.	4.5	102
25	Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination. Nano Letters, 2020, 20, 1499-1509.	4.5	61
26	Synthesis of Ultrathin Biotite Nanosheets as an Intelligent Theranostic Platform for Combination Cancer Therapy. Advanced Science, 2019, 6, 1901211.	5.6	130
27	Stimuli-Responsive Polymer–Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy. Nano Letters, 2019, 19, 5967-5974.	4.5	101
28	2D Monoelemental Germanene Quantum Dots: Synthesis as Robust Photothermal Agents for Photonic Cancer Nanomedicine. Angewandte Chemie, 2019, 131, 13539-13544.	1.6	41
29	2D Monoelemental Germanene Quantum Dots: Synthesis as Robust Photothermal Agents for Photonic Cancer Nanomedicine. Angewandte Chemie - International Edition, 2019, 58, 13405-13410.	7.2	102
30	Emerging two-dimensional monoelemental materials (Xenes) for biomedical applications. Chemical Society Reviews, 2019, 48, 2891-2912.	18.7	482
31	Drug Delivery Strategies for the Treatment of Metabolic Diseases. Advanced Healthcare Materials, 2019, 8, e1801655.	3.9	40
32	Nanobuffering of pH-Responsive Polymers: A Known but Sometimes Overlooked Phenomenon and Its Biological Applications. ACS Nano, 2019, 13, 4876-4882.	7.3	77
33	Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes <i>p53</i> -deficient cancers to mTOR inhibition. Science Translational Medicine, 2019, 11, .	5.8	177
34	Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy. ACS Nano, 2019, 13, 357-370.	7.3	204
35	Drug loading augmentation in polymeric nanoparticles using a coaxial turbulent jet mixer: Yong investigator perspective. Journal of Colloid and Interface Science, 2019, 538, 45-50.	5.0	12
36	Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy. Trends in Biotechnology, 2018, 36, 562-575.	4.9	139

#	Article	IF	CITATIONS
37	Intracellular Mechanistic Understanding of 2D MoS <sub>2</sub> Nanosheets for Anti-Exocytosis-Enhanced Synergistic Cancer Therapy. ACS Nano, 2018, 12, 2922-2938.	7.3	188
38	Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery. Theranostics, 2018, 8, 6008-6024.	4.6	19
39	Cancer Theranostics: Twoâ€Dimensional Antimoneneâ€Based Photonic Nanomedicine for Cancer Theranostics (Adv. Mater. 38/2018). Advanced Materials, 2018, 30, 1870283.	11.1	3
40	Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nature Biomedical Engineering, 2018, 2, 850-864.	11.6	214
41	Redoxâ€Responsive Nanoparticleâ€Mediated Systemic RNAi for Effective Cancer Therapy. Small, 2018, 14, e1802565.	5.2	85
42	Twoâ€Dimensional Antimoneneâ€Based Photonic Nanomedicine for Cancer Theranostics. Advanced Materials, 2018, 30, e1802061.	11.1	314
43	Flat Cell Culturing Surface May Cause Misinterpretation of Cellular Uptake of Nanoparticles. Advanced Biology, 2018, 2, 1800046.	3.0	7
44	Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. Nano Letters, 2018, 18, 4618-4625.	4.5	173
45	Abstract 4642: Personalized cancer-specific protein corona affects the therapeutic impact of nanoparticles. Cancer Research, 2018, 78, 4642-4642.	0.4	6
46	Personalized protein corona on nanoparticles and its clinical implications. Biomaterials Science, 2017, 5, 378-387.	2.6	227
47	Hyper-cell-permeable micelles as a drug delivery carrier for effective cancer therapy. Biomaterials, 2017, 123, 118-126.	5.7	43
48	Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano, 2017, 11, 2618-2627.	7.3	172
49	Cancer immunotherapy: Wound-bound checkpoint blockade. Nature Biomedical Engineering, 2017, 1, .	11.6	15
50	Antimonene Quantum Dots: Synthesis and Application as Nearâ€Infrared Photothermal Agents for Effective Cancer Therapy. Angewandte Chemie - International Edition, 2017, 56, 11896-11900.	7.2	465
51	Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Letters, 2017, 17, 4427-4435.	4.5	119
52	Antimonene Quantum Dots: Synthesis and Application as Nearâ€Infrared Photothermal Agents for Effective Cancer Therapy. Angewandte Chemie, 2017, 129, 12058-12062.	1.6	93
53	Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation. ACS Applied Materials & Interfaces, 2017, 9, 11440-11450.	4.0	28
54	Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nature Communications, 2017, 8, 777.	5.8	507

#	Article	IF	CITATIONS
55	Nanomedicine for safe healing of bone trauma: Opportunities and challenges. Biomaterials, 2017, 146, 168-182.	5.7	57
56	Multiscale technologies for treatment of ischemic cardiomyopathy. Nature Nanotechnology, 2017, 12, 845-855.	15.6	104
57	Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in <i>Ldlr<sup>â^'/â^'</sup></i> Mice. Advanced Healthcare Materials, 2017, 6, 1700313.	3.9	63
58	ROSâ€Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy. Advanced Materials, 2017, 29, 1700141.	11.1	370
59	Cellular uptake of nanoparticles: journey inside the cell. Chemical Society Reviews, 2017, 46, 4218-4244.	18.7	1,709
60	Evolution of macromolecular complexity in drug delivery systems. Nature Reviews Chemistry, 2017, 1, .	13.8	233
61	Challenges in DNA Delivery and Recent Advances in Multifunctional Polymeric DNA Delivery Systems. Biomacromolecules, 2017, 18, 2231-2246.	2.6	147
62	Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 2017, 17, 20-37.	12.8	4,153
63	A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 713-722.	1.7	38
64	Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona. Trends in Biotechnology, 2017, 35, 257-264.	4.9	313
65	A Big Year Ahead for Nano in 2018. ACS Nano, 2017, 11, 11755-11757.	7.3	1
66	Emerging Advances in Nanotheranostics with Intelligent Bioresponsive Systems. Theranostics, 2017, 7, 3915-3919.	4.6	48
67	Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery <i>In Vitro</i> and <i>In Vivo</i> . Theranostics, 2017, 7, 1990-2002.	4.6	81
68	Polymeric Nanoparticles Amenable to Simultaneous Installation of Exterior Targeting and Interior Therapeutic Proteins. Angewandte Chemie - International Edition, 2016, 55, 3309-3312.	7.2	121
69	Ultraâ€pHâ€Responsive and Tumorâ€Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Antiâ€Cancer Efficacy. Angewandte Chemie - International Edition, 2016, 55, 7091-7094.	7.2	216
70	Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5552-5557.	3.3	127
71	Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano, 2016, 10, 5280-5292.	7.3	170
72	Targeted nanoparticles for colorectal cancer. Nanomedicine, 2016, 11, 2443-2456.	1.7	117

#	Article	IF	CITATIONS
73	Emerging understanding of the protein corona at the nano-bio interfaces. Nano Today, 2016, 11, 817-832.	6.2	205
74	Nanomedicines for renal disease: current status and future applications. Nature Reviews Nephrology, 2016, 12, 738-753.	4.1	179
75	Ultraâ€pHâ€Responsive and Tumorâ€Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Antiâ€Cancer Efficacy. Angewandte Chemie, 2016, 128, 7207-7210.	1.6	10
76	The Use of Silk in Nanomedicine Applications. Advances in Delivery Science and Technology, 2016, , 245-278.	0.4	4
77	Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7750-7755.	3.3	73
78	Polymeric Nanoparticles Amenable to Simultaneous Installation of Exterior Targeting and Interior Therapeutic Proteins. Angewandte Chemie, 2016, 128, 3370-3373.	1.6	10
79	Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chemical Reviews, 2016, 116, 2602-2663.	23.0	2,018
80	Nanotechnology for protein delivery: Overview and perspectives. Journal of Controlled Release, 2016, 240, 24-37.	4.8	294
81	Hydrophobic Cysteine Poly(disulfide)â€based Redoxâ€Hypersensitive Nanoparticle Platform for Cancer Theranostics. Angewandte Chemie - International Edition, 2015, 54, 9218-9223.	7.2	164
82	Drug Delivery Nanocarriers from a Fully Degradable PEG onjugated Polyester with a Reductionâ€Responsive Backbone. Chemistry - A European Journal, 2015, 21, 11325-11329.	1.7	26
83	Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Science Translational Medicine, 2015, 7, 275ra20.	5.8	269
84	Effect of PEG Pairing on the Efficiency of Cancer-Targeting Liposomes. Theranostics, 2015, 5, 746-754.	4.6	61
85	Nanomedicines for endothelial disorders. Nano Today, 2015, 10, 759-776.	6.2	49
86	Cancer nanomedicine: from targeted delivery to combination therapy. Trends in Molecular Medicine, 2015, 21, 223-232.	3.5	578
87	Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E156-65.	3.3	364
88	Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7779-7784.	3.3	170
89	A mucosal vaccine against <i>Chlamydia trachomatis</i> generates two waves of protective memory T cells. Science, 2015, 348, aaa8205.	6.0	312
90	Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opinion on Drug Delivery, 2015, 12, 1459-1473.	2.4	206

#	Article	IF	CITATIONS
91	Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nature Communications, 2015, 6, 8692.	5.8	353
92	Platelet mimicry. Nature, 2015, 526, 47-48.	13.7	40
93	Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Science Translational Medicine, 2015, 7, 314ra183.	5.8	273
94	Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis. Advanced Healthcare Materials, 2015, 4, 228-236.	3.9	66
95	Annexin A1–containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. Journal of Clinical Investigation, 2015, 125, 1215-1227.	3.9	257
96	Aptamer Bioconjugates for Cancer Therapy. , 2015, , 339-342.		0
97	Development of Therapeutic Polymeric Nanoparticles for the Resolution of Inflammation. Advanced Healthcare Materials, 2014, 3, 1448-1456.	3.9	26
98	Fourth Annual Conference of the American Society for Nanomedicine. Journal of NeuroImmune Pharmacology, 2014, 9, 1-38.	2.1	2
99	Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer. ACS Nano, 2014, 8, 6056-6065.	7.3	217
100	Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1078-1083.	3.3	171
101	Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews, 2014, 66, 2-25.	6.6	2,275
102	A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins. Nano Letters, 2014, 14, 6449-6455.	4.5	36
103	Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers. Angewandte Chemie - International Edition, 2014, 53, 8975-8979.	7.2	122
104	Polymer- and Protein-Based Nanotechnologies for Cancer Theranostics. , 2014, , 419-436.		12
105	Current Progress of Aptamer-Based Molecular Imaging. Journal of Nuclear Medicine, 2014, 55, 353-356.	2.8	91
106	Insight into nanoparticle cellular uptake and intracellular targeting. Journal of Controlled Release, 2014, 190, 485-499.	4.8	624
107	Polymeric Nanoparticle Technologies for Oral Drug Delivery. Clinical Gastroenterology and Hepatology, 2014, 12, 1605-1610.	2.4	122
108	Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10287-10292.	3.3	234

#	Article	IF	CITATIONS
109	Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine, 2014, 32, 2882-2895.	1.7	144
110	Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 401-409.	1.7	134
111	Hybrid lipid–polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, e897-e900.	1.7	76
112	Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chemical Communications, 2013, 49, 9392.	2.2	16
113	Synthesis of Polymer–Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy. Bioconjugate Chemistry, 2013, 24, 1429-1434.	1.8	104
114	Single Step Reconstitution of Multifunctional High-Density Lipoprotein-Derived Nanomaterials Using Microfluidics. ACS Nano, 2013, 7, 9975-9983.	7.3	104
115	Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18638-18643.	3.3	302
116	Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery. Science Translational Medicine, 2013, 5, 213ra167.	5.8	326
117	HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy. Journal of Materials Chemistry B, 2013, 1, 4576.	2.9	14
118	Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine, 2013, 8, 687-698.	1.7	65
119	Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on <i>In Vivo</i> Properties. ACS Nano, 2013, 7, 5675-5683.	7.3	89
120	Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy. ACS Nano, 2013, 7, 10671-10680.	7.3	196
121	Spontaneous Formation of Heterogeneous Patches on Polymer–Lipid Core–Shell Particle Surfaces during Selfâ€Assembly. Small, 2013, 9, 511-517.	5.2	17
122	Surface Charge-Switching Polymeric Nanoparticles for Bacterial Cell Wall-Targeted Delivery of Antibiotics. ACS Nano, 2012, 6, 4279-4287.	7.3	447
123	Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection. ACS Nano, 2012, 6, 696-704.	7.3	148
124	Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Advanced Drug Delivery Reviews, 2012, 64, 1363-1384.	6.6	365
125	DNA Selfâ€Assembly of Targeted Nearâ€Infraredâ€Responsive Gold Nanoparticles for Cancer Thermoâ€Chemotherapy. Angewandte Chemie - International Edition, 2012, 51, 11853-11857.	7.2	299
126	Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nature Nanotechnology, 2012, 7, 623-629.	15.6	571

#	Article	IF	CITATIONS
127	Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chemical Communications, 2012, 48, 5835.	2.2	76
128	α <sub>V</sub> β <sub>3</sub> Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug. ACS Nano, 2012, 6, 4530-4539.	7.3	281
129	Mass Production and Size Control of Lipid–Polymer Hybrid Nanoparticles through Controlled Microvortices. Nano Letters, 2012, 12, 3587-3591.	4.5	189
130	Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine, 2012, 63, 185-198.	5.0	1,347
131	Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chemical Society Reviews, 2012, 41, 2971.	18.7	1,469
132	Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Science Translational Medicine, 2012, 4, 128ra39.	5.8	978
133	Aptamer-Functionalized Nanoparticles for Medical Applications: Challenges and Opportunities. ACS Nano, 2012, 6, 3670-3676.	7.3	149
134	Nanoparticles for Targeted and Temporally Controlled Drug Delivery. Nanostructure Science and Technology, 2012, , 9-29.	0.1	51
135	Using ligands to target cancer cells. Clinical Advances in Hematology and Oncology, 2012, 10, 543-4.	0.3	8
136	Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1850-1855.	3.3	467
137	Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation. Accounts of Chemical Research, 2011, 44, 1123-1134.	7.6	416
138	Advances in Drug Delivery. Annual Review of Materials Research, 2011, 41, 1-20.	4.3	125
139	Synthesis of Sizeâ€Tunable Polymeric Nanoparticles Enabled by 3D Hydrodynamic Flow Focusing in Singleâ€Layer Microchannels. Advanced Materials, 2011, 23, H79-83.	11.1	200
140	MICROFLUIDICS: Synthesis of Size-Tunable Polymeric Nanoparticles Enabled by 3D Hydrodynamic Flow Focusing in Single-Layer Microchannels (Adv. Mater. 12/2011). Advanced Materials, 2011, 23, H78-H78.	11.1	5
141	Differentially Charged Hollow Core/Shell Lipid–Polymer–Lipid Hybrid Nanoparticles for Small Interfering RNA Delivery. Angewandte Chemie - International Edition, 2011, 50, 7027-7031.	7.2	156
142	Selfâ€Propelled Microrockets to Capture and Isolate Circulating Tumor Cells. Angewandte Chemie - International Edition, 2011, 50, 7220-7221.	7.2	10
143	Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials, 2011, 32, 6226-6233.	5.7	169
144	In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19347-19352.	3.3	121

#	Article	IF	CITATIONS
145	Aptamer bioconjugates for Cancer Therapy. , 2011, , 257-259.		Ο
146	Progress in siRNA Delivery Using Multifunctional Nanoparticles. Methods in Molecular Biology, 2010, 629, 53-67.	0.4	32
147	Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine, 2010, 5, 269-285.	1.7	201
148	Poly(ethylene glycol) with Observable Shedding. Angewandte Chemie - International Edition, 2010, 49, 6567-6571.	7.2	65
149	On firm ground: IP protection of therapeutic nanoparticles. Nature Biotechnology, 2010, 28, 1267-1270.	9.4	75
150	Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2213-2218.	3.3	231
151	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17939-17944.	3.3	545
152	Nanoparticle Technologies for Cancer Therapy. Handbook of Experimental Pharmacology, 2010, , 55-86.	0.9	262
153	ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine, 2010, 5, 361-368.	1.7	95
154	Polymeric Nanoparticles for Drug Delivery. Methods in Molecular Biology, 2010, 624, 163-175.	0.4	226
155	Single-Step Assembly of Homogenous Lipidâ^'Polymeric and Lipidâ^'Quantum Dot Nanoparticles Enabled by Microfluidic Rapid Mixing. ACS Nano, 2010, 4, 1671-1679.	7.3	283
156	pH-Responsive Nanoparticles for Drug Delivery. Molecular Pharmaceutics, 2010, 7, 1913-1920.	2.3	806
157	Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Letters, 2010, 10, 3223-3230.	4.5	1,369
158	PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials, 2009, 30, 1627-1634.	5.7	620
159	Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials, 2009, 30, 2231-2240.	5.7	240
160	Impact of Nanotechnology on Drug Delivery. ACS Nano, 2009, 3, 16-20.	7.3	2,760
161	Multifunctional nanoparticles for prostate cancer therapy. Expert Review of Anticancer Therapy, 2009, 9, 211-221.	1.1	23
162	Nanoparticles for Cancer Diagnosis and Therapy. Nanostructure Science and Technology, 2009, , 209-235.	0.1	5

#	Article	IF	CITATIONS
163	Formulation/Preparation of Functionalized Nanoparticles for In Vivo Targeted Drug Delivery. Methods in Molecular Biology, 2009, 544, 589-598.	0.4	48
164	Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem, 2008, 3, 1311-1315.	1.6	297
165	HERâ€⊉â€Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy. ChemMedChem, 2008, 3, 1839-1843.	1.6	143
166	The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials, 2008, 29, 1216-1223.	5.7	63
167	Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy, 2008, 8, 1063-1070.	1.4	225
168	Nanotechnology for drug delivery: the perfect partnership. Expert Opinion on Drug Delivery, 2008, 5, 927-929.	2.4	71
169	Nanotechnology and aptamers: applications in drug delivery. Trends in Biotechnology, 2008, 26, 442-449.	4.9	247
170	New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 74-85.	0.8	274
171	Microfluidic Platform for Controlled Synthesis of Polymeric Nanoparticles. Nano Letters, 2008, 8, 2906-2912.	4.5	728
172	Self-Assembled Lipidâ^'Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. ACS Nano, 2008, 2, 1696-1702.	7.3	851
173	Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17356-17361.	3.3	904
174	Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles. Molecular Pharmaceutics, 2008, 5, 505-515.	2.3	2,993
175	Microfluidic Synthesis of Polymeric Nanoparticles. , 2008, , .		3
176	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2586-2591.	3.3	649
177	Nanofabrication and Microfabrication of Functional Materials for Tissue Engineering. Tissue Engineering, 2007, 13, 1867-1877.	4.9	117
178	Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine, 2007, 2, 669-680.	1.7	219
179	Co-Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates. ChemMedChem, 2007, 2, 1268-1271.	1.6	245
180	Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2, 14-21.	6.2	431

#	Article	IF	CITATIONS
181	Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2, 751-760.	15.6	7,469
182	Quantum Dotâ^'Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer. Nano Letters, 2007, 7, 3065-3070.	4.5	950
183	Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28, 869-876.	5.7	1,151
184	Nanofabrication and Microfabrication of Functional Materials for Tissue Engineering. Tissue Engineering, 2007, .	4.9	1
185	Nanoparticle-Aptamer Bioconjugates for Targeted Antineoplastic Drug Delivery. American Journal of Drug Delivery, 2006, 4, 123-130.	0.6	4
186	Drug delivery systems in urology—getting "smarter― Urology, 2006, 68, 463-469.	0.5	31
187	Aptamers and Cancer Nanotechnology. , 2006, , 289-313.		2
188	Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components. Biomaterials, 2006, 27, 1479-1486.	5.7	220
189	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6315-6320.	3.3	1,595
190	Nanoparticle–aptamer bioconjugates for cancer targeting. Expert Opinion on Drug Delivery, 2006, 3, 311-324.	2.4	245
191	Nanomedicine: Developing smarter therapeutic and diagnostic modalitiesâ~†. Advanced Drug Delivery Reviews, 2006, 58, 1456-1459.	6.6	726
192	Magnetically Responsive Polymeric Microparticles for Oral Delivery of Protein Drugs. Pharmaceutical Research, 2006, 23, 557-564.	1.7	122
193	An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform. Angewandte Chemie - International Edition, 2006, 45, 8149-8152.	7.2	552
194	Magnetite-PLGA Microparticles for Oral Delivery of Insulin. Materials Research Society Symposia Proceedings, 2005, 873, 1.	0.1	0
195	Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with Cells. Analytical Chemistry, 2005, 77, 5453-5459.	3.2	159
196	Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays. Lab on A Chip, 2005, 5, 1380.	3.1	224
197	Nanoparticle-Aptamer Bioconjugates. Cancer Research, 2004, 64, 7668-7672.	0.4	873
198	CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras andjunD. Blood, 2003, 101, 4033-4041.	0.6	41

#	Article	IF	CITATIONS
199	During Differentiation of the Monocytic Cell Line U937, Purα Mediates Induction of the <i>CD11c</i> β2 Integrin Gene Promoter. Journal of Immunology, 2002, 168, 3887-3893.	0.4	43
200	Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms. American Journal of Physiology - Cell Physiology, 2001, 281, C649-C661.	2.1	82
201	CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA. Nucleic Acids Research, 2000, 28, 2256-2267.	6.5	13
202	Protein kinase C activation downregulates the expression and function of the basolateral Na+/K+/2Cl? cotransporter. Journal of Cellular Physiology, 1999, 181, 489-498.	2.0	20
203	Effects of bryostatin 1, a novel anticancer agent, on intestinal transport and barrier function: Role of protein kinase C. Surgery, 1998, 124, 380-387.	1.0	16